US private equity firm TPG, a prominent public shareholder of Sai Life Sciences Ltd., made a complete exit from the company in a bulk deal worth Rs 2,675 crore, as per NSE bulk data.
TPG affiliate TPG Asia VII SF Pte offloaded 3.07 crore shares (14.72%) between Rs 871.01 to Rs 871.86 apiece; while Societe Generale bought 14.06 lakh shares (0.67%) at Rs 871 apiece, Goldman Sachs (Singapore) Pte bought 11.04 lakh shares (0.53%) at Rs 871 apiece.
IIFL Capital Services Ltd., Kotak Securities Ltd. and Jefferies India Pvt. were the bookrunners for the deal.
The public shareholder owned 24.73% stake in the company, as per BSE data recorded until March 31, 2025. However, it offloaded 10% of its shares at Rs 722 per piece. This was after 48% equity of Sai Life Sciences became eligible for trade as the six-month lock-in period ends for shareholders, as per Nuvama's report.
Sai Life Sciences is an innovator-focused contract research, development, and manufacturing organisation based in Hyderabad.
The company offers comprehensive end-to-end services across the entire drug discovery, development and manufacturing value chain. Specialising in small molecule new chemical entities, Sai Life Sciences caters to global pharmaceutical and biotechnology companies.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
